As a Free StocksGuide user, you can view scores for all 7,015 stocks worldwide.
17 Analysts have issued a Cabaletta Bio Inc forecast:
17 Analysts have issued a Cabaletta Bio Inc forecast:
Jun '25 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | -145 -145 |
47%
47%
|
EBIT (Operating Income) EBIT | -149 -149 |
49%
49%
|
Net Profit | -144 -144 |
60%
60%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Cabaletta Bio, Inc. operates as a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in April 2017 and is headquartered in Philadelphia, PA.
Head office | United States |
CEO | Steven Nichtberger |
Employees | 163 |
Founded | 2017 |
Website | www.cabalettabio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.